Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156129 | 0.89 | CA1 (0.42) | CA2CA1CA9 | |
| SCHEMBL3765248 | 0.85 | LMNA (0.36) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL3766342 | 0.73 | CA1 (0.39) | CA2CA1CA9 | |
| SCHEMBL255956 | 0.72 | TSHR (0.44) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL31655439 | 0.72 | TSHR (0.44) | CYP2C9LMNACA2CA1CA9 | |
| Cyclopropane SCHEMBL2363143 | 0.71 | TSHR (0.42) | CYP2C9LMNACA2CA1CA9 | |
| Methane SCHEMBL10428157 | 0.71 | TSHR (0.42) | CYP2C9LMNACA2CA1CA9 | |
| Cyclopropane SCHEMBL2363620 | 0.69 | TSHR (0.41) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL1156126 | 0.69 | — | — | |
| SCHEMBL407166 | 0.67 | TSHR (0.48) | CYP2C9LMNACA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | CYP2C9 1199/4885LMNA 3914/4885CA2 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.